Erasca Inc is a biotechnology company focused on developing innovative therapies to treat cancer by targeting specific genetic drivers of the disease. The company is dedicated to advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in oncology. By harnessing modern scientific advancements and a deep understanding of tumor biology, Erasca seeks to improve patient outcomes and enhance the overall standard of care in cancer treatment. The organization prioritizes collaboration with various stakeholders to drive the progress of its research and development initiatives in the competitive biopharmaceutical landscape. Read More
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment paradigms for historically difficult cancers. Leading researchers showcased breakthrough advances in immunotherapy at recent oncology conferences, highlighting next-generation approaches that selectively target tumor-specific vulnerabilities. This wave of innovation is propelling companies developing targeted therapies across gastrointestinal, blood, and solid tumor cancers, including Oncolytics Biotech Inc. (NASDAQ: ONCY), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Erasca, Inc. (NASDAQ: ERAS), Immuneering Corporation (NASDAQ: IMRX), and Prelude Therapeutics Incorporated (NASDAQ: PRLD).
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in a fireside chat on Thursday, February 8, 2024 at 11:00 am Eastern Time. Drs. Lim and Chacko will also participate in one-on-one investor meetings.
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
